Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.
PBLS · Parabilis Medicines, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.
Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.
Parabolus plans to initiate the global pedestal Phase Three study of Zolucatetide in the first half next year, following an FDA-agreed induction-maintenance regimen; desmoid data showed 62% ORR at 24 months and 72% ORR at 32 weeks.
Parabilis Medicines, Inc. amended its headquarters lease to add 33,525 square feet beginning January 1, 2028, extend the term through December 31, 2037, and provide an option for two additional five-year periods.